Patterns of care and survival for lung cancer: Results of the European population-based high-resolution study

Milena Sant; Caterina Daidone; Kaire Innos; Rafael Marcos-Gragera; Katrijn Vanschoenbeek; Miguel Rodriguez Barranco; Ester Oliva Poch; Roberto Lillini; Lung Cancer HR Study Working Group

doi:10.3389/fepid.2023.1109853

Patterns of care and survival for lung cancer: Results of the European population-based high-resolution study

Front Epidemiol. 2023 Mar 3:3:1109853. doi: 10.3389/fepid.2023.1109853. eCollection 2023.

Authors

Affiliations

¹ Analytical Epidemiology and Health Impact Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
² Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia.
³ Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
⁴ Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology (ICO), Girona, Spain.
⁵ Biomedical Research Institute (IdiBGi), Girona, Spain.
⁶ Belgium Cancer Registry, Bruxelles, Belgium.
⁷ Granada Cancer Registry, Granada, Spain.
⁸ Andalusian School of Public Health (EASP), Granada, Spain.
⁹ Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), Girona, Spain.
¹⁰ Girona Cancer Registry, Girona, Spain.
¹¹ Radiation Oncology Department, Catalan Institute of Oncology Hospital Trueta, Girona, Spain.

Abstract

Objectives: To investigate differences in lung cancer (LC) management and survival using data from European population cancer registries.

Methods: We analysed 4,602 lung cancer cases diagnosed in 2010-2013, followed-up to 2019 in five countries. Multivariable logistic regression was used to calculate the Odds Ratio (OR) of surgery for stages I-II LC or chemo- or radiotherapy for stages III-IV LC. Relative survival (RS) was estimated by the actuarial method; Relative Excess Risk of death (RER), with 95% CI, was calculated by generalized linear models.

Results: Diagnostic work-up was extensive for 65.9% patients (range 57%, Estonia, Portugal - 85% (Belgium). Sixty-six percent of stages I-II patients underwent surgery; compared to non-operated, their adjusted OR decreased with age and was associated with main bronchus cancer (OR vs. lobes 0.25, CI, 0.08-0.82), stage II (OR vs. stage I: 0.42, CI, 0.29-0.60), comorbidity (OR vs. absent: 0.55, CI, 0.33-0.93), country (ORs: Estonia 1.82, CI, 1.28-2.60; Belgium 0.62, CI, 0.42-0.91; Portugal 0.69, CI, 0.52-0.93).Almost half of stages III-IV patients received chemo- or radiotherapy only; the adjusted OR vs. non receiving decreased with age and was associated with unspecified cancer topography or morphology. The adjusted five-year RER increased with age and stage and was lower for women (0.78, CI, 0.72-0.86), above the reference for main bronchus cancer (1.37, CI, 1.21-1.54) and unspecified morphology (1.17, CI, 1.05-1.30). Surgery carried the lowest mortality (RS 56.9; RER 0.13, CI, 0.11-0.15) with RER above the mean in Estonia (1.20, CI, 1.10-1.30), below it in Portugal (0.88, CI, 0.82-0.93) and Switzerland (0.91, CI, 0.84-0.99). Comorbidity (1.21, CI, 1.09-1.35) and not smoking (0.68, CI, 0.57-0.81) were associated with RER.

Conclusions: The survival benefit of early diagnosis, allowing curative surgery, was evident at the population level. Screening for subjects at risk and adhesion to standard care should be incremented across the EU by funding better equipment and training health personnel.

Keywords: comorbidity; lung cancer; population registries; smoking; survival.

Grants and funding

This work was carried out in the framework of the EUROPEAN HIGH RESOLUTION CANCER STUDIES and partially funded by Italian Ministry of Health “Ricerca Corrente” funds. The work of Kaire Innos was supported by Estonian Research Council (grant no PRG722).